ZURAZura Bio Limited
$4.12+3.3% 1Y
$4.12
$3.2152 weeks$7.04
ZURA in its own filings
ZURA's filing record carries 2 kinds of hard flag, each is shown beside the share of the whole market carrying the same one, because more than half of all companies carry at least one.
180
Events found in the filings · across 442 filings · the record starts in 2021
- Hard flags
- 2
Hard flags
- Most recent filing
- Aug 17, 2026
Most recent filing · Form 8-K
- Record starts
- May 5, 2021
Record starts · the earliest filing Ryufin holds for this name
Details›
- Next results filingsame week as a year ago
- expected around Nov 12, 2026
- Restatement admitted (non-reliance)historical
- 2022-04-08
- Change in certifying accountantpast_3y
- 2024-02-23
- Late periodic report2 occurrences
- 2022-03-31
- Security removed from listing or deregistered2 occurrences · usually a matured note or preferred class, not the common shares
- 2024-08-27
- SEC comment-letter activity40 occurrences
- 2025-06-03
SEC EDGAR submissions index and 8-K item codes; 4.02 and 1.03 items are confirmed against the filing text.
What the company said
The company's own words from its current reports to the SEC, newest first
- Aug 17, 2026Forward-Looking Statements Disclaimer.Regulation FD disclosure · press release
- Aug 11, 2026Zura Bio Reports Second Quarter 2026 Financial Results and Recent Corporate Updates.Earnings release · press release
- Jul 1, 2026Forward-looking statements disclaimer.Regulation FD disclosure · press release
- Jun 18, 2026Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers On June 17, 2026, Zura Bio Limited (the “Company”) held its Annual General Meeting of Shareholders (the “Annual Meeting”), at which a quorum was present.Director or officer change · Form 8-K
- May 22, 2026Director Resignation On May 20, 2026, Someit Sidhu notified Zura Bio Limited (the “Company”) of his decision to resign from the board of directors of the Company effective as of May 21, 2026.Director or officer change · Form 8-K
- May 7, 2026Zura Bio Reports First Quarter 2026 Financial Results and Recent Corporate Updates.Earnings release · press release
- Apr 23, 2026Transition of Chief Financial Officer On April 20, 2026, Eric Hyllengren, the Company’s Chief Financial Officer, Principal Financial Officer and Principal Accounting Officer, was separated from the Company.Director or officer change · Form 8-K
- Mar 19, 2026Zura Bio Reports Full Year 2025 Financial Results.Earnings release · press release
- Mar 10, 2026Forward-looking statements disclaimer.Regulation FD disclosure · press release
- Mar 5, 2026Bio to Present Phase 2 TibuSURE Study Design Poster Evaluating Dual IL-17A and BAFF Inhibition in Systemic Sclerosis at 9th Systemic.Regulation FD disclosure · press release
- Feb 26, 2026On February 24, 2026, Zura Bio Limited (the “Company ’) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Piper Sandler & Co. and Cantor Fitzgerald & Co., as representatives of the several underwriters listed therein (collectively, the “Underwriters”), pursuant to which …Material agreement entered · Form 8-K
Quoted from SEC EDGAR filings. A current report is filed within four business days of the event it describes.
opening the record…